NYSEHealth CareHealthcare PlansSnapshot 2026-07-31
Reading HUM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain EPS guidance of at least $9.00 for FY 2026: guidance $9.00 vs target $9.00.
View ThesisRevenue growth is accelerating — up about 14% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 47% in its worst 12-month stretch.
View RiskHumana's growth depends on maintaining its EPS guidance of at least $9.00 for FY 2026. The company recently beat earnings expectations with a 22% surprise and 26% revenue growth. It trades at 21× P/E, slightly below the 22× peer median, indicating it looks expensive. The primary risk is the pressure on EPS guidance, with a 12% chance of missing next quarter. Peer multiples imply a price about 8% below where it trades. This read is provisional.
Trailing returns as of 2026-07-31. HUM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 30 analysts currently covering HUM (as of Jul 2026).
Based on 18 Wall Street analysts offering 12-month price targets for HUM in the last 4 months.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Exiting plans could negatively impact Medicare Advantage ratings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $363.86
The last 12 months of price, then the range of analyst 12-month targets from today’s $363.86.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Maintain EPS guidance of at least $9.00 for FY 2026
Profits align with cost management, aiding EPS guidance.
Acquisition interest indicates strong market position and growth potential.
Acquisition offer enhances growth potential and strategic positioning.
Illinois win enhances revenue potential and margin outlook.
New Medicaid program enhances growth potential and revenue.
Sale of Gentiva stake enhances capital allocation strategy.
Earnings beat indicates strong performance towards EPS guidance.
